Leading the way to fast RDS success

CUROSURF® (poractant alfa) Intratracheal Suspension is the #1 surfactant used worldwide, and the number of infants treated continues to grow.

If you haven’t used CUROSURF in your NICU, you may be surprised to learn some interesting facts about how many NICUs in the US and worldwide are experiencing CUROSURF.

  • More infants are treated with CUROSURF each year than with any other surfactant5
  • The number of hospitals using CUROSURF has nearly tripled across the US since 20045
  • 20 years of clinical practice with over 1 million infants6


Map comparing hospitals using CUROSURF in 2004 versus 2009



Ongoing research that keeps pace with clinical practice

  • Safety and efficacy established in 17 clinical trials, evaluating over 4000 patients6
  • Growing clinical portfolio of over 30 published articles6
  • The surfactant most widely studied for use with less invasive ventilation strategies1,6
  • Continuing support dedicated to the advancement of neonatology research and the treatment of RDS

Download an overview of our broad clinical portfolio

For further reading, consider exploring these other published studies.


Next: Experience CUROSURF® (poractant alfa) in your NICU

If you are interested in evaluating CUROSURF, the CUROSURF Experience Program can help you smoothly integrate CUROSURF into your NICU.
Learn More
Explore the unique benefits of CUROSURF, such as efficient administration, rapid onset, fewer doses, and support for less invasive ventilation.
Learn More

Clinical studies have not established that fewer doses, lower volume, or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.


Further reading

Indication

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS)
in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia is recommended prior to CUROSURF administration. Surfactant administration can be expected to reduce the severity of RDS but will not eliminate the mortality and morbidity associated with other complications of prematurity.

Pulmonary Hemorrhage is a known complication of premature birth and very low birth-weight and has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700-2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

Please see full prescribing information.

This site is intended for United States residents only.

References: 1. CUROSURF® (poractant alfa) Intratracheal Suspension prescribing information, Cornerstone Therapeutics Inc, September 2009. 2. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. Am J Perinatol. 2004;21:109-119. 3. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child. 1995;72:F8-F13. 4. Malloy CA, Nicoski P, Muraskas JK. Acta Paediatr. 2005;94:779-784. 5. IMS DDD Lung Surfactant Market Purchases May 2004 to December 2009. 6. Data on file, Chiesi Farmaceutici, S.p.A. and Cornerstone Therapeutics Inc.